See more : Brenmiller Energy Ltd (BNRG) Income Statement Analysis – Financial Results
Complete financial analysis of Cytocom, Inc. (CBLI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cytocom, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LaSalle LOGIPORT REIT (3466.T) Income Statement Analysis – Financial Results
- Wynn Macau, Limited (1128.HK) Income Statement Analysis – Financial Results
- Wendt (India) Limited (WENDT.NS) Income Statement Analysis – Financial Results
- GreenPower Motor Company Inc. (GPV.V) Income Statement Analysis – Financial Results
- Flagstar Bancorp, Inc. (FBC) Income Statement Analysis – Financial Results
Cytocom, Inc. (CBLI)
About Cytocom, Inc.
Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.94K | 1.11M | 1.14M | 1.95M | 3.52M | 2.71M | 3.70M | 8.49M | 3.57M | 8.79M | 15.33M | 14.35M | 4.71M | 2.02M | 1.71M | 1.14M | 636.34K | 75.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 262.94K | 1.11M | 1.14M | 1.95M | 3.52M | 2.71M | 3.70M | 8.49M | 3.57M | 8.79M | 15.33M | 14.35M | 4.71M | 2.02M | 1.71M | 1.14M | 636.34K | 75.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 691.07K | 1.66M | 3.62M | 5.05M | 6.50M | 7.14M | 9.65M | 19.53M | 22.50M | 22.79M | 16.14M | 14.33M | 13.16M | 17.43M | 6.99M | 2.64M | 2.89M | 0.00 |
| General & Administrative | 2.16M | 1.82M | 2.32M | 2.50M | 3.38M | 6.36M | 8.47M | 12.04M | 11.12M | 11.11M | 9.93M | 6.40M | 5.89M | 10.53M | 2.14M | 986.42K | 262.82K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 1.82M | 2.32M | 2.50M | 3.38M | 6.36M | 8.47M | 12.04M | 11.12M | 11.11M | 9.93M | 6.40M | 5.89M | 10.53M | 2.14M | 986.42K | 262.82K | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.85M | 3.47M | 5.94M | 7.55M | 9.87M | 13.50M | 18.12M | 31.56M | 33.62M | 33.90M | 26.07M | 20.73M | 19.05M | 27.96M | 9.13M | 3.63M | 3.16M | 0.00 |
| Cost & Expenses | 2.85M | 3.47M | 5.94M | 7.55M | 9.87M | 13.50M | 18.12M | 31.56M | 33.62M | 33.90M | 26.07M | 20.73M | 19.05M | 27.96M | 9.13M | 3.63M | 3.16M | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 99.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.96K | 0.00 | 0.00 | 11.20K | 17.99K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.45K | 13.78K | 18.18K | 21.08K | 63.46K | 140.14K | 200.79K | 471.21K | 479.60K | 525.51K | 407.29K | 362.14K | 324.35K | 188.40K | 94.93K | 44.76K | 2.30K | -211.83K |
| EBITDA | -2.39M | -2.63M | -3.59M | -9.69M | -2.60M | -12.40M | 1.83M | -16.79M | -30.05B | -3.49M | 0.00 | -12.46M | -13.70M | 0.00 | -7.12M | -2.32M | -2.52M | -136.83K |
| EBITDA Ratio | -907.81% | -236.50% | -315.75% | -497.10% | -73.77% | -457.79% | 49.43% | -197.83% | -497.23% | -39.68% | -169.32% | -86.87% | -291.18% | -1,328.08% | -416.61% | -204.04% | -396.15% | -182.43% |
| Operating Income | -2.59M | -2.36M | -4.80M | -5.60M | -6.36M | -10.79M | -14.42M | -23.08M | -30.05M | -25.11M | -10.74M | -6.38M | -14.35M | -25.94M | -7.42M | -2.49M | -2.52M | 75.00K |
| Operating Income Ratio | -983.70% | -212.03% | -421.72% | -287.46% | -180.65% | -398.45% | -389.58% | -271.88% | -841.47% | -285.60% | -70.03% | -44.49% | -304.86% | -1,285.18% | -434.26% | -218.45% | -395.93% | 100.00% |
| Total Other Income/Expenses | 148.68K | -333.83K | 1.09M | -4.24M | 3.77M | -2.25M | 14.46M | 2.95M | 7.63M | 19.88M | -16.03M | -6.46M | 414.73K | -2.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -2.44M | -2.69M | -3.71M | -9.84M | -2.59M | -13.04M | 35.37K | -20.13M | -22.41M | -5.23M | -26.77M | -12.85M | -13.93M | -28.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -927.15% | -242.02% | -325.73% | -505.18% | -73.61% | -481.68% | 0.96% | -237.15% | -627.74% | -59.49% | -174.61% | -89.55% | -296.04% | -1,387.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 148.68K | -333.83K | 1.09M | -4.24M | 3.77M | -2.15M | 14.46M | 2.95M | 7.63M | 19.88M | -16.03M | -6.46M | 414.73K | -2.06M | 11.20K | 17.99K | 0.00 | 211.83K |
| Net Income | -2.40M | -2.65M | -3.61M | -9.71M | -2.66M | -12.64M | 1.63M | -17.26M | -18.23M | -4.01M | -26.37M | -12.83M | -14.03M | -27.00M | -7.22M | -2.39M | -2.52M | -136.83K |
| Net Income Ratio | -912.16% | -237.73% | -317.34% | -498.19% | -75.57% | -466.64% | 44.01% | -203.38% | -510.66% | -45.66% | -171.97% | -89.41% | -298.07% | -1,337.42% | -422.82% | -209.55% | -396.51% | -182.43% |
| EPS | -0.19 | -0.23 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -2.47 | -20.14 | -15.64 | -20.79 | -44.66 | -16.22 | -7.64 | -10.93 | -0.01 |
| EPS Diluted | -0.19 | -0.23 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -2.47 | -20.14 | -15.64 | -20.79 | -44.66 | -16.22 | -7.64 | -10.93 | -0.01 |
| Weighted Avg Shares Out | 12.40M | 11.30M | 11.29M | 11.19M | 10.99M | 7.06M | 2.70M | 2.25M | 1.87M | 1.63M | 1.31M | 820.26K | 674.62K | 604.52K | 445.31K | 312.52K | 230.78K | 15.48M |
| Weighted Avg Shares Out (Dil) | 12.40M | 11.30M | 11.29M | 11.19M | 10.99M | 7.06M | 2.70M | 2.25M | 1.87M | 1.63M | 1.31M | 820.26K | 674.62K | 604.52K | 445.31K | 312.52K | 230.78K | 15.48M |
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for...
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business...
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday,...
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
FORT COLLINS, Colo. and BUFFALO, N.Y.
CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Cleveland BioLabs, Inc. (Nasdaq: CBLI) increased by over 15% pre-market. This is why it happened.
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
FORT COLLINS, Colo. and BUFFALO, N.Y.
Source: https://incomestatements.info
Category: Stock Reports